» Articles » PMID: 12608471

Prevalence and Clinical Implications of Hepatitis B Virus Genotypes in Southern Taiwan

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2003 Mar 1
PMID 12608471
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Hepatitis B virus (HBV) infection is a major health problem. HBV genotypes may be associated with progression of liver disease. The distribution and clinical implications of HBV genotypes in southern Taiwan are evaluated.

Methods: We used a polymerase chain reaction-restriction fragment length polymorphism genotyping method to determine HBV genotypes.

Results: The genotype distribution for 265 patients with chronic HBV infection was as follows: A, 3 (1%); B, 158 (60%); C, 90 (34%); D, 7 (2.5%); E, 0: F, 0; and unclassified, 7 (2.5%). Compared with genotype B patients, genotype C patients had a higher hepatitis B e antigen positive rate and higher fibrosis score. There was no significant difference in the mean age between genotype B and genotype C patients with hepatocellular carcinoma (HCC). However, when patients were stratified by age, the prevalence of genotype C was significantly higher in young HCC patients (<50 years of age) than in age-matched asymptomatic carriers (40% versus 10%, P < 0.001). Using multivariate analysis, the significant risk factors for advanced liver disease (cirrhosis or HCC) for patients with chronic HBV infection were old age, male gender and genotype C.

Conclusions: These results suggest that genotype C is associated with more severe liver diseases than the B variant.

Citing Articles

A Recent Prevalence of Hepatitis B Virus (HBV) Genotypes and Subtypes in Asia: A Systematic Review and Meta-Analysis.

Bello K, Mat Jusoh T, Irekeola A, Abu N, Mohd Amin N, Mustaffa N Healthcare (Basel). 2023; 11(7).

PMID: 37046937 PMC: 10094200. DOI: 10.3390/healthcare11071011.


Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.

Tseng T, Kuo Y, Hu T, Hung C, Wang J, Lu S Viruses. 2022; 14(6).

PMID: 35746660 PMC: 9227936. DOI: 10.3390/v14061189.


Outcomes of hepatitis B immunoglobulin and hepatitis B vaccination in high-risk newborns born to HBeAg-positive mothers.

Wu C, Huang W, Chen C, Lu S Biomed J. 2021; 45(5):798-805.

PMID: 34801765 PMC: 9661494. DOI: 10.1016/j.bj.2021.11.007.


ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.

Squires K, Mayers D, Bluemling G, Kolykhalov A, Guthrie D, Reddy P Antimicrob Agents Chemother. 2020; 64(9).

PMID: 32540975 PMC: 7449170. DOI: 10.1128/AAC.00836-20.


Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.

Ma T, Hu T, Hung C, Wang J, Lu S, Chen C PLoS One. 2019; 14(10):e0222221.

PMID: 31584951 PMC: 6777800. DOI: 10.1371/journal.pone.0222221.